EMS18d
FDA approves clot-dissolving agent for treatment of acute ischemic stroke
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
Medscape29d
Single-Dose Intravenous Salbutamol Bolus for Managing Children With Acute Severe Asthma in the Emergency Department: Reanalysis of Data
[27] We consider the use of a single-dose intravenous salbutamol bolus in the ED to be more effective in achieving earlier clinical response in a subgroup of children with acute severe asthma.
Medscape11d
FDA Okays Tenecteplase for Acute Ischemic Stroke
The drug is administered as a single, 5-second intravenous bolus — a faster and simpler administration compared to the standard of care 60-minute infusion of alteplase (Activase; Genentech), the ...
Nature2mon
Basal-bolus insulin regimen is effective for hospitalized patients with type 2 diabetes
compared the efficacy and safety of a basal-bolus insulin regimen with that of sliding-scale regular insulin (SSI) in hospitalized general medical patients with type 2 diabetes. The prospective ...
The Manhattan Mercury9d
FDA Approves TNKase for Acute Ischemic Stroke
The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
PipelineReview.com11d
FDA Approves Genentech’s TNKase®in Acute Ischemic Stroke in Adults
TNKase ® (tenecteplase) is the first stroke medicine approved by the FDA in nearly 30 years – – Single five-second intravenous bolus provides faster and simpler administr ...